Juniper Pharmaceuticals Inc, formerly Columbia Laboratories Inc is engaged in the business of developing, manufacturing and selling pharmaceutical products that utilize its proprietary bioadhesive drug delivery technologies to treat various medical conditions. It is focused in developing drugs that improve treatment options for women's health, an area where it have a rich heritage and capabilities. It has developed and brought to market five bioadhesive vaginal gel products that provide patient-friendly solutions for infertility, pregnancy support, amenorrhea, and other gynecologic conditions. The Company's Progesterone Products include Crinone and Prochieve. Crinone is a sustained release gel that delivers natural progesterone vaginally. Crinone utilizes the company's patented BDS, which enables the progesterone to achieve a preferential uptake of drug from the vagina to the uterus, or a "First Uterine Pass Effect." The Company operates in two segments: product and service. The product segment oversees the supply chain and manufacturing of CRINONE, its sole commercialized product to commercial partner, Merck KGaA, internationally. The product segment also includes the royalty stream it receives from Allergan, for CRINONE sales in the United States as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing, and analytical and consulting services provided to the Company's customers, as well as characterizing and developing pharmaceutical product candidates for internal programs and managing the preclinical and clinical manufacturing of COL-1077 and IVR technology. It's Crinone and Prochieve vaginal gel products are manufactured in bulk by Fleet Laboratories Limited, Watford, Herts, United Kingdom ("Fleet") and filled into overwrapped single-use disposable applicators by Maropack AG, Zell, Switzerland ("Maropack"). Its customers include trade customers, such as drug wholesalers, specialty pharmacies, and chain drug stores, and its marketing partners. The Company and its marketing partners compete against established pharmaceutical and consumer product companies which market products addressing similar needs.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.